JP2023509512A5 - - Google Patents

Info

Publication number
JP2023509512A5
JP2023509512A5 JP2022541714A JP2022541714A JP2023509512A5 JP 2023509512 A5 JP2023509512 A5 JP 2023509512A5 JP 2022541714 A JP2022541714 A JP 2022541714A JP 2022541714 A JP2022541714 A JP 2022541714A JP 2023509512 A5 JP2023509512 A5 JP 2023509512A5
Authority
JP
Japan
Prior art keywords
cells
isolated
chain
population
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022541714A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509512A (ja
JP7793523B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/012444 external-priority patent/WO2021142081A1/en
Publication of JP2023509512A publication Critical patent/JP2023509512A/ja
Publication of JP2023509512A5 publication Critical patent/JP2023509512A5/ja
Application granted granted Critical
Publication of JP7793523B2 publication Critical patent/JP7793523B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022541714A 2020-01-07 2021-01-07 人工多能性幹細胞を用いたt細胞集団の製造方法 Active JP7793523B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062957939P 2020-01-07 2020-01-07
US62/957,939 2020-01-07
PCT/US2021/012444 WO2021142081A1 (en) 2020-01-07 2021-01-07 Methods of producing t cell populations using induced pluripotent stem cells

Publications (3)

Publication Number Publication Date
JP2023509512A JP2023509512A (ja) 2023-03-08
JP2023509512A5 true JP2023509512A5 (cg-RX-API-DMAC7.html) 2023-11-15
JP7793523B2 JP7793523B2 (ja) 2026-01-05

Family

ID=74626090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022541714A Active JP7793523B2 (ja) 2020-01-07 2021-01-07 人工多能性幹細胞を用いたt細胞集団の製造方法

Country Status (4)

Country Link
US (1) US20230036952A1 (cg-RX-API-DMAC7.html)
EP (1) EP4087916A1 (cg-RX-API-DMAC7.html)
JP (1) JP7793523B2 (cg-RX-API-DMAC7.html)
WO (1) WO2021142081A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021222479A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US9206394B2 (en) * 2010-02-03 2015-12-08 The University Of Tokyo Method for reconstructing immune function using pluripotent stem cells
JPWO2011096482A1 (ja) * 2010-02-03 2013-06-13 国立大学法人 東京大学 多能性幹細胞を用いた免疫機能再建法
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
EP2853590B1 (en) * 2012-05-22 2018-11-07 The University of Tokyo Method for producing antigen-specific t cells
JP6555058B2 (ja) * 2015-09-30 2019-08-07 アイシン精機株式会社 車両用画像処理装置
CA3048996A1 (en) * 2015-12-08 2017-06-15 Regents Of The University Of Minnesota Human t cell derived from t cell-derived induced pluripotent stem cell and methods of making and using
JP7653759B2 (ja) * 2016-01-20 2025-03-31 フェイト セラピューティクス,インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法

Similar Documents

Publication Publication Date Title
US20220204933A1 (en) Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
CN104321425B (zh) 用于诱导和扩增源自外周血单个核细胞的自然杀伤细胞的方法
CA2848121C (en) Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
JP2019536461A5 (cg-RX-API-DMAC7.html)
WO2019138217A1 (en) Method for transducing cells with a viral vector for the expression of a chimeric antigen receptor (car) or transgenic t-cell receptor (tcr)
WO2014017533A1 (ja) T細胞受容体のクローニング方法
JP2020506713A (ja) 多能性幹細胞から模倣自然免疫細胞を生成する方法及びキット
KR20220031541A (ko) 항-bcma car t 세포의 제조
Liang et al. Single-cell transcriptomics reveals killing mechanisms of antitumor cytotoxic CD4+ TCR-T cells
US20250152628A1 (en) Tcr targeting cytomegalovirus antigen, t cell expressing tcr, and application
US9205111B2 (en) Process for producing engineered targeted T cell and medicine
Manca et al. Anti-HIV genetic treatment of antigen-specific human CD4 lymphocytes for adoptive immunotherapy of opportunistic infections in AIDS
CN118591397A (zh) 通用型car-t细胞的制备技术及其应用
US20220233596A1 (en) Modified NK-92 cells, and therapeutic and diagnostic uses thereof
CN113832101A (zh) 自然杀伤细胞体外高效扩增的制备方法
JP7725014B2 (ja) HTLV-1がコードするTax抗原特異的細胞傷害性Tリンパ球のT細胞受容体又はその機能的断片
EP4538366A1 (en) Enhancing lineage stability of therapeutic regulatory t cell products
CA2501087C (en) Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer
TW202615096A (zh) SARS-CoV-2感染症治療及/或預防用細胞及其製法
JP2023504196A5 (cg-RX-API-DMAC7.html)
Chin et al. T-cell receptor v-Beta usage of tumor-infiltrating lymphocyte lines cloned from human breast-tumor and melanoma
JP2025515116A5 (cg-RX-API-DMAC7.html)
WO2025196582A1 (en) A method for preparing chimeric antigen receptor (car) expressing cells
CN121673419A (zh) 一种工程化t细胞受体、表达其的现货型工程免疫细胞以及在肿瘤中的应用
WO2024190905A1 (ja) Hpv特異的細胞傷害性t細胞のt細胞受容体又はその機能的断片